Hepatocellular carcinoma (HCC), the most common form of liver cancer, continues to pose a significant global health challenge ...

A new study reveals how a critical imbalance in bile acids—the substances made by the liver that help digest fats—can trigger ...

LIVER CANCER, the third leading cause of cancer-related deaths globally, is primarily attributed to hepatocellular carcinoma ...

Background: Hepatoblastoma (HBL) and hepatocellular carcinoma (HCC) are respectively the first and the second most common pediatric malignant liver tumors. The purpose of this study was to ...

Systemic therapy represents the standard of care treatment for patients with advanced hepatocellular carcinoma (HCC). Given ...

Long-term use of statins may delay or deflect the development of hepatocellular carcinoma in adults with chronic liver disease, as well as in the general population, emerging research, including ...

HCC occurred in 1.27% of patients with PBC, which is lower than the recommended threshold for cost-effective surveillance.

The US Food and Drug Administration (FDA) has granted approval for Bristol Myers Squibb’s (BMS) Opdivo (nivolumab) in combination with Yervoy (ipilimumab) as a first-line treatment for adults with ...

The clinical trial will include nearly 150 patients with advanced hepatocellular carcinoma that expresses glypican-3.